Thu, Jul 24, 2014, 11:43 AM EDT - U.S. Markets close in 4 hrs 17 mins

Recent

% | $
Click the to save as a favorite.

ONYX Pharmaceuticals, Inc. Message Board

  • roxettewish roxettewish Sep 4, 2012 7:41 PM Flag

    ONXX drug halted for causing two deaths

    this puppy is toast now

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Hey trolls, how it that toast tasting today? I can still give you some butter so you can ease its path when I tell you to shove it.

    • That toast appears pretty dry and worthless. Do you want some butter to go with it?

      • 1 Reply to dr.vinmantoo
      • September 12, 2012 12:23 PM

        In a report published Wednesday, Maxim Group reiterated its Buy rating on Onyx Pharmaceuticals (NASDAQ: ONXX [FREE Stock Trend Analysis]), and raised its price target from $92.00 to $95.00.

        Maxim Group noted, “We believe Kyprolis sales are the major near-term driver of ONXX. Our randomized talks with oncologists suggest that the drug is broadly recognized by doctors and that most doctors will likely prescribe the drug according to its approved indication, relapsed and refractory multiple myeloma (MM) patients with at least two prior therapies. Meanwhile, many oncologists are open to the ideas of using Kyprolis as a first-line therapy once supporting trial data become available. Both the conversion of 003-A1 trial participants to paying patients and new prescriptions could drive sales. That said, we believe consensus expectations could run ahead of actual Kyprolis sales.”

 
ONXX
124.700.00(0.00%)Sep 30 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.